Diadema Partners LP Makes New Investment in Replimune Group, Inc. (NASDAQ:REPL)

Diadema Partners LP bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 114,000 shares of the company's stock, valued at approximately $1,381,000. Diadema Partners LP owned approximately 0.17% of Replimune Group as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares during the last quarter. Barclays PLC raised its position in Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after purchasing an additional 98,791 shares during the period. Victory Capital Management Inc. bought a new stake in Replimune Group in the fourth quarter worth $543,000. Swiss National Bank boosted its position in Replimune Group by 57.4% during the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock valued at $1,256,000 after buying an additional 37,800 shares during the period. Finally, State Street Corp grew its stake in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Down 0.1 %

REPL stock traded down $0.01 on Friday, reaching $9.05. The company's stock had a trading volume of 362,638 shares, compared to its average volume of 866,625. The firm has a market cap of $696.99 million, a PE ratio of -2.95 and a beta of 1.26. The business has a fifty day simple moving average of $10.34 and a two-hundred day simple moving average of $11.68. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on REPL. JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.